

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



波司登國際控股有限公司

**Bosideng International Holdings Limited**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 3998)**

### **CLARIFICATION ANNOUNCEMENT**

References are made to the announcements of Bosideng International Holdings Limited (the “**Company**”) dated June 24, 2019 (the “**Announcements**”) for clarification of certain allegations made in a report issued by Bonitas Research LLC (“**Bonitas**”) on or about June 24, 2019 (the “**Report**”). The Company noted that a further report was published by Bonitas on June 26, 2019 allegedly to rebut the clarifications made by the Company in the Announcements (the “**Further Report**”).

The Company takes the view that the so-called “rebuttal” of Bonitas made in the Further Report is, similar to the Report, comprises statements which are misleading, biased, selective, inaccurate and incomplete as well as groundless allegations and irresponsible speculations. The Company denies all the allegations made in the Report and the Further Report. The Company will provide additional information in due course, as appropriate.

In view of the potential damage to the Company, the Company is in progress of taking all necessary actions, including without limitations, instituting such legal proceedings against such entity(ies) or associated individual(s) responsible for the Report and the Further Report.

**Shareholders and potential investors are reminded to exercise extreme caution when dealing in the securities of the Company.**

By order of the Board

**Bosideng International Holdings Limited**

**Gao Dekang**

Chairman

Hong Kong, June 26, 2019

*As at the date of this announcement, the executive Directors are Mr. Gao Dekang, Ms. Mei Dong, Ms. Huang Qiaolian, Mr. Rui Jinsong and Mr. Gao Xiaodong; and the independent non-executive Directors are Mr. Dong Binggen, Mr. Wang Yao, and Dr. Ngai Wai Fung.*